Vilazodone
Product Images NDC 42291-948

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone (NDC 42291-948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (10mg Label)

Vilazodone HCl Tablets 10 mg label by AvKARE. The label indicates 30 tablets per package, for prescription use only. It includes instructions to dispense with the medication guide and storage conditions, along with a barcode and QR code. The label lists the manufacturer as AvKARE in Pulaski, TN.*

FDA Label Image

20 (20mg Label)

Packaging label for Vilazodone HCl Tablets by AvKARE, containing 20 mg strength tablets. The label displays the AvKARE logo, NDC 42291-949-30, and specifies a bottle size of 30 tablets. It includes storage instructions and manufacturer information for AvKARE Pharmaceuticals in Pulaski, TN.*

FDA Label Image

40 (40mg Label)

Label for Vilazodone HCl Tablets, 40 mg strength, manufactured by AvKARE. The label indicates the package contains 30 tablets and includes storage instructions, dosage guidance, and safety warnings. It also features the NDC number 42291-950-30 and advises dispensing the medication guide available on AvKARE's website.*

FDA Label Image

The Structural Formula For Vilazodone HCl (Vilazodone Tablets 01)

Chemical structure of Vilazodone Hydrochloride, showing the molecular arrangement of atoms including a cyano group, piperazine ring, and an amide functional group.*

FDA Label Image

Figure 1. Effect Of Other Drugs On Vilazodone Pharmacokinetics (Vilazodone Tablets 02)

A forest plot chart showing pharmacokinetic changes in Vilazodone when co-administered with ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole). It displays fold changes and 90% confidence intervals for Cmax and AUC relative to a reference baseline.*

FDA Label Image

Figure 2. Impact Of Vilazodone On Other Drug Pharmacokinetics (Vilazodone Tablets 03)

A forest plot depicting fold changes and 90% confidence intervals in pharmacokinetic parameters for various CYP substrates and P-gp substrates. Substrates listed include nifedipine, caffeine, debrisoquine, flurbiprofen, mephenytoin, and digoxin with parameters such as AUCp, CRmp, URmp, CLrm, Um, Cmax, and AUC compared relative to reference values shown on a horizontal axis ranging from 0.5 to 2.0.*

FDA Label Image

Figure 3: Impact Of Intrinsic Factors On Vilazodone Pharmacokinetics (Vilazodone Tablets 04)

A forest plot chart displaying fold change and 90% confidence intervals of pharmacokinetic parameters Cmax and AUC for Vilazodone across different population subgroups, including age over 65, female gender, renal impairment (mild, moderate, severe), and hepatic impairment (mild, moderate, severe). The chart shows the relative change compared to reference subjects.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.